These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 16774153)

  • 1. Detection of autoantibodies against hypocretin, hcrtrl, and hcrtr2 in narcolepsy: anti-Hcrt system antibody in narcolepsy.
    Tanaka S; Honda Y; Inoue Y; Honda M
    Sleep; 2006 May; 29(5):633-8. PubMed ID: 16774153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Search for neuron-specific and nonneuron-specific antibodies in narcoleptic patients with and without HLA DQB1*0602.
    Black JL; Krahn LE; Pankratz VS; Silber M
    Sleep; 2002 Nov; 25(7):719-23. PubMed ID: 12405606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-resolution HLA sequencing and hypocretin receptor 2 autoantibodies in narcolepsy type 1 and type 2.
    Hamdan S; Wasling P; Lind A
    Int J Immunogenet; 2024 Oct; 51(5):310-318. PubMed ID: 38898624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sleep, sleep disorders and hypocretin (orexin).
    Mignot E
    Sleep Med; 2004 Jun; 5 Suppl 1():S2-8. PubMed ID: 15301991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study of the diagnostic utility of HLA typing, CSF hypocretin-1 measurements, and MSLT testing for the diagnosis of narcolepsy in 163 Korean patients with unexplained excessive daytime sleepiness.
    Hong SC; Lin L; Jeong JH; Shin YK; Han JH; Lee JH; Lee SP; Zhang J; Einen M; Mignot E
    Sleep; 2006 Nov; 29(11):1429-38. PubMed ID: 17162989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absence of anti-hypocretin receptor 2 autoantibodies in post pandemrix narcolepsy cases.
    Luo G; Lin L; Jacob L; Bonvalet M; Ambati A; Plazzi G; Pizza F; Leib R; Adams CM; Partinen M; Mignot EJ
    PLoS One; 2017; 12(12):e0187305. PubMed ID: 29220370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system.
    Nishino S; Kanbayashi T
    Sleep Med Rev; 2005 Aug; 9(4):269-310. PubMed ID: 16006155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DLA-DQB1 alleles and bone marrow transplantation experiments in narcoleptic dogs.
    Wagner JL; Storb R; Storer B; Mignot E
    Tissue Antigens; 2000 Sep; 56(3):223-31. PubMed ID: 11034558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Narcolepsy: immunological aspects.
    Overeem S; Black JL; Lammers GJ
    Sleep Med Rev; 2008 Apr; 12(2):95-107. PubMed ID: 18291691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of the ICSD-2 criteria for CSF hypocretin-1 measurements in the diagnosis of narcolepsy in the Danish population.
    Knudsen S; Jennum PJ; Alving J; Sheikh SP; Gammeltoft S
    Sleep; 2010 Feb; 33(2):169-76. PubMed ID: 20175400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoantibodies in Pandemrix
    Wallenius M; Lind A; Akel O; Karlsson E; Svensson M; Arvidsson E; Ramelius A; Törn C; Palm L; Lernmark Å; Elding Larsson H
    Autoimmunity; 2019 Jun; 52(4):185-191. PubMed ID: 31328572
    [No Abstract]   [Full Text] [Related]  

  • 12. Hypocretin (orexin) levels in cerebrospinal fluid of patients with narcolepsy: relationship to cataplexy and HLA DQB1*0602 status.
    Krahn LE; Pankratz VS; Oliver L; Boeve BF; Silber MH
    Sleep; 2002 Nov; 25(7):733-6. PubMed ID: 12405608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypocretin receptor expression in canine and murine narcolepsy models and in hypocretin-ligand deficient human narcolepsy.
    Mishima K; Fujiki N; Yoshida Y; Sakurai T; Honda M; Mignot E; Nishino S
    Sleep; 2008 Aug; 31(8):1119-26. PubMed ID: 18714784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and neurobiological aspects of narcolepsy.
    Nishino S
    Sleep Med; 2007 Jun; 8(4):373-99. PubMed ID: 17470414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of hypocretin (orexin) antibodies in patients with narcolepsy.
    Black JL; Silber MH; Krahn LE; Fredrickson PA; Pankratz VS; Avula R; Walker DL; Slocumb NL
    Sleep; 2005 Apr; 28(4):427-31. PubMed ID: 16171287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HLA DQB1*06:02 negative narcolepsy with hypocretin/orexin deficiency.
    Han F; Lin L; Schormair B; Pizza F; Plazzi G; Ollila HM; Nevsimalova S; Jennum P; Knudsen S; Winkelmann J; Coquillard C; Babrzadeh F; Strom TM; Wang C; Mindrinos M; Fernandez Vina M; Mignot E
    Sleep; 2014 Oct; 37(10):1601-8. PubMed ID: 25197808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Diagnosis of childhood narcolepsy and significance of HLA in its diagnosis].
    Wu HS; Guo YH; Zou LP; Han F; Zhang WC; Fang F; Xiao J; Ding CH; Li J; Chen CH
    Zhonghua Er Ke Za Zhi; 2004 Apr; 42(4):248-51. PubMed ID: 15157381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monozygotic twins concordant for narcolepsy-cataplexy without any detectable abnormality in the hypocretin (orexin) pathway.
    Khatami R; Maret S; Werth E; Rétey J; Schmid D; Maly F; Tafti M; Bassetti CL
    Lancet; 2004 Apr; 363(9416):1199-200. PubMed ID: 15081654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Narcolepsy-cataplexy and schizophrenia in adolescents.
    Huang YS; Guilleminault C; Chen CH; Lai PC; Hwang FM
    Sleep Med; 2014 Jan; 15(1):15-22. PubMed ID: 24268496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical spectrum of narcolepsy with cataplexy: a reappraisal.
    Sturzenegger C; Bassetti CL
    J Sleep Res; 2004 Dec; 13(4):395-406. PubMed ID: 15560774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.